Belt and Road Summit 2025- Deal-making

10–16 Sept 2025 | China (Hong Kong)

Register
Register
Register

ProjectUpdated on 5 September 2025

Next Generation Fluorescent Nanoparticles For Early Detection of Biomarkers 用于早期检测生物标志物的下一代荧光纳米粒子

Laurent Koehler

Co-Founder and CBDO at HK-Dtech Limited

Hong Kong, China (Hong Kong)

About

HK-Dtech/Poly-Dtech revolutionizes immunoassays with ultra-fluorescent lanthanide nanoparticles, enabling rapid, simple, high-performance, and cost-effective single or multiplex tests using a standard microplate reader, meeting users’ needs with unparalleled efficiency, in both R&D and IVD fields:

In Research & Discovery, we help accelerating research with our ultra-fluorescent lanthanide nanoparticles and ready-to-use kits. Designed for simplicity, speed, and precision, our solutions support applications from basic science to advanced drug discovery, optimizing user’s workflow while maintaining high performance.

 Regarding In-Vitro-Diagnostic, we deliver advanced immunoassays, including LFIA, TR-FRET, FLISA, and multiplexing solutions. From concept to final product, we ensure superior sensitivity, specificity, ease of use, and high adaptability, serving a wide range of fields, including life sciences, clinical diagnostics, veterinary health, industrial testing, and food safety.

 Seize the investment opportunity in the next disruptive technology that is ready for commercialization and poised to revolutionize both rapid testing and multiplexing sectors, becoming the benchmark in the industry

 HK-Dtech / Poly-Dtech 以超高荧光镧系纳米颗粒革新免疫分析技术,通过标准微孔板阅读器实现快速、简便、高性能且经济高效的单项或多重检测,满足用户在研发和体外诊断(IVD)领域的高效需求:

 在科研与发现领域,我们的超高荧光镧系纳米颗粒和即用型试剂盒助力加速研究进程。产品设计注重简便、快速和精准,支持从基础科学到先进药物研发的多种应用,在保持高性能的同时,优化用户的工作流程。

在体外诊断领域,我们提供先进的免疫分析解决方案,包括侧流免疫层析(LFIA)、时间分辨荧光共振能量转移(TR-FRET)、荧光免疫吸附分析(FLISA)及多重检测方案。从概念到成品,我们确保产品具备卓越的灵敏度、特异性、易用性和高适应性,广泛应用于生命科学、临床诊断、兽医健康、工业检测和食品安全等领域。

 把握投资机遇,这项即将商业化的颠覆性技术,将重新定义快速检测和多重检测市场,成为行业新标杆。

Project Location

  • China (Hong Kong)

Project Format

  • Private Project

ESG (Environmental, Social, and Governance)

  • Yes

Project Stage

  • Operations

Main Project Sector

  • Technology

Technology

  • Bio-Tech

Total Project Value

  • 25,000,001 to 50,000,000 USD

Investment Capital Required

  • 7,500,001 to 10,000,000 USD

Interested Format of Cooperation

  • Minority Shareholdings

Preferred Financing Model

  • Equity

Previous Funding Stage

  • Seed & Pre-Series

Main Service(s) Required

  • Financial Services

Financial Services

  • Private Equity & Venture Capital

Organisation

HK-Dtech Limited

Shatin, China (Hong Kong)

Similar opportunities